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Background: A traditional Chinese Medicine (TCM) formula, HZJW, has been applied in clinics in China for
gastrointestinal disorders. However, the therapeutic mechanism underlying its efficacy and safety remained to be
defined. The present investigation was undertaken to evaluate the formula HZJW for its gastroprotective potential,
possible effect on Helicobacter pylori along with safety to justify its anti-ulcer action and safe clinical application.
Methods: The gastroduodenal cytoprotective potential was evaluated in rodent experimental models (HCl/Ethanol
and NSAID-induced ulcer protocols). The anti-H. pylori property was assessed by agar dilution assay in vitro and
analysis in vivo including rapid urease test, immunogold test and histopathology. For toxicity assessment, acute toxicity
study was performed according to fixed dose procedure with a single oral administration of HZJW to mice. In the oral
chronic toxicity, rats (80 males, 80 females) were administrated HZJW orally in 0, 1000, 2500, or 5000 mg/kg/day doses
for 26 weeks (n = 40/group of each sex). Clinical signs, mortality, body weights, feed consumption, ophthalmology,
hematology, serum biochemistry, gross findings, organ weights and histopathology were examined at the end of the
13- and 26-week dosing period, as well as after the 4-week recovery period.
Results: In the HCl/Ethanol-induced ulcer model, it was observed that oral administration with HZJW (260, 520 and
1040 mg/kg) and ranitidine (250 mg/kg) significantly reduced the ulcerative lesion index (116.70 ± 36.4, 102.20 ± 18.20,
84.10 ± 12.1 and 73.70 ± 16.70) in a dose-dependent manner, respectively, with respect to control group (134.10 ± 31.69).
Significant inhibition was also observed in ulcerative index from aspirin-induced ulcer model, with decreases of 35.40 ±
5.93, 31.30 ± 8.08, 26.80 ± 8.27and 20.40 ± 6.93 for the groups treated with HZJW and ranitidine, in parallel to controls
(41.60 ± 10.80). On the other hand, treatment with HZJW efficaciously eradicated H. pylori in infected mice in rapid
urease test (RUT) and immunogold antibody assay, as further confirmed by reduction of H. pylori presence in
histopathological analysis. In the in vitro assay, MICs for HZJW and amoxicillin (positive control) were 125 and 0.12 μg/mL
respectively. The LD50 of HZJW was over 18.0 g/kg for mice. No drug-induced abnormalities were found as clinical signs,
body weight, food consumption, hematology, blood biochemistry, ophthalmology and histopathology results across
three doses. No target organ was identified. The No Observed Adverse Effect Level (NOAEL) of HZJW was determined to
be 5,000 mg/kg/day for both sexes, a dose that was equivalent to 50 times of human dose.
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Conclusions: These results suggested the efficacy and safety of HZJW in healing peptic ulcer and combating H. pylori,
which corroborated their conventional indications and contributed to their antiulcer pharmacological validation, lending
more credence to its clinical application for the traditional treatment of stomach complaints symptomatic of peptic ulcer
disease (PUD). HZJW might have the potential for further development as a safe and effective alternative/complementary
to conventional medication in treating gastrointestinal (GI) disorders.
Keywords: HZJW, TCM, Cytoprotective, Helicobacter pylori, Gastroduodenal ulcer, SafetyTable 1 Composition of HZJW
Linnean classification Botanical origin Weight ratio
Macrocephalae Rhizoma Atractylodes macrocephala
Koidz.
0.2
Scutellariae Barabtae Herba Scutellaria barbata D. Don 0.15
Corydalis Rhizoma Corydalis yanhusuo
W.T. Wang
0.12








Alpiniae Officmarum Rhizoma Alpinia officinarum Hance 0.03
Coptidis Rhizoma Coptis chinensis Franch. 0.06
Perillae Fructus Perilla frutescens (L.) Britt. 0.12
Taraxact Herba Taraxacum mongolicum
Hand. Maza.
0.15
Typhae Pollen Typha angustifolia L. 0.12
Hedyotis diffusa Willd Olydenlandia diffusa
(Wild.) Roxb.
0.3
Herba Eupatorii Eupatorium fortunei Turcz. 0.15Background
Gastric and duodenal ulcers (peptic ulcers) are the most
common gastrointestinal disorder that occur in clinical
practice and are currently considered as a progressive global
health problem. The ulcers that affect the gastrointestinal
system are normally provoked by an imbalance between
aggressive and protective factors in the stomach [1].
Furthermore, it is also widely accepted that most peptic
ulcers are associated with Helicobacter pylori infection and
eradiation of this organism leads to enhanced ulcer healing
and much less chance of ulcer recurrence [2,3].The current
medicinal treatment of peptic ulcer is generally based on
triple therapy regimen, inhibition of gastric acid secretion
by histamine H2-antagonists, proton pump inhibitors, as
well as on mucosal protective therapy provided by sucral-
fate and bismuth [4]. However, the treatment is complicated
and of high cost, requiring a minimum of two antibiotics in
combination with gastric acid inhibitors, which often causes
nausea, antibiotic resistance, recurrence and other adverse
effects [5-7]. In view of their various harmful adverse effects
and the prevalence of antibiotic-resistant H. pylori strains,
the search for safe and effective non-antibiotic agents is
essential. In recent years, active researches have rekindled
interest in natural drugs possessing these activities,
and there has been an increased inclination towards
herbal formulations, which are widely appreciated by
the population especially in oriental countries.
For centuries, herbals have been used traditionally for
the treatment of a wide range of ailments, including
gastrointestinal (GI) disorders [8,9], such as dyspepsia,
gastritis and peptic ulcer disease (PUD). In China, a
variety of Chinese medicinal herbs have been prescribed
to attenuate or eradicate gastritis-like disorders and
achieved good effects. HZJW, composed of 12 medicinal
herbs, is a Chinese herbal formula based on a famous
proved recipe proposed by Prof. Honglin Xing (Table 1).
HZJW had clinical efficacy of reinforcing spleen and
stomach to clear away heat and eliminate dampness,
promoting qi and blood circulation to relieve pain and
flatulence, and had been demonstrated to possess
pronounced effectiveness and safety for the treatment
of gastrointestinal disease in clinical practice [10,11].
Traditionally, these twelve herbs with well-established
histories of application are commonly prescribed togetherwith other herbs in herbal formulas to treat gastro-
intestinal disorders by Chinese medicine practitioners.
According to the theory of TCM, a reasonable combination
of medicinal herbs was used to enhance the desired action
and eliminate possible side effects. Corydalis Rhizoma,
Coptidis Rhizoma and Alpinia officinarum, important
components of HZJW, were proved to be effective in the
prevention of H. pylori infection [12,13]. Berberine
and its protoberberine alkaloids palmatine, coptisine
and aporphinoid alkaloid of magnoflorine have been
confirmed to be the major pharmacologically active con-
stituents of Coptidis Rhizoma against H. pylori [14-16].
Berberin, one of the chemical marker of this formula, was
also found to possess simultaneous gastrointestine
protective and anti-inflammatory activities [15].
In clinical practice in China, we have successfully applied
this recipe for treating patients with gastrointestinal
disorders. Nevertheless, the evidence-based mechanism
of the reputed efficacy remains elusive. No standard
preclinical toxicity data in any animal species are currently
available to assess its potential toxic effects. The present
research was to explore possible mechanisms underlying
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comprehensive toxicological properties. In view of the
critical role of cytoprotective and anti-H. pylori activity in
the management of peptic ulcer, the development of a
single preparation endowed with both properties will
be a welcome contribution. Firstly, we assessed the
gastroprotective activity via different rodent experimental
models (HCl/Ethanol and NSAID-induced ulcer protocols).
Secondly, we determined the anti-H. pylori effect of HZJW
in vitro by agar dilution assay and in vivo via rapid urease
test, immunogold assay and histopathological examination.
Thirdly, we undertook an acute toxicity appraisal in
Kun-ming mice and a 26-week chronic toxicological
study on Sprague–Dawley rats to characterize its possible
toxicity. The present scheme should contribute to an
improved understanding of possible mechanisms of
HZJW and, also valuable information of toxicity to direct
its clinical application.
Methods
Sources and authentication of herbs
All the herbs of HZJW formula were obtained from
Yifang Chinese Material Medica Business Department,
Yulin City, all of which are authenticated by Prof.
Lai Xiaoping at Guangzhou University of Chinese
Medicine. The authenticated voucher specimens
(Voucher #20090924) were kept in School of Chinese
Materia Medica, Guangzhou University of Chinese
Medicine (GUCM). Assurance of quality control for all
the materials was validated according to Pharmacopoeia
of the People's Republic of China [17].
Preparation of HZJW
HZJW was composed of 12 medicinal herbs as shown in
Table 1. Coptidis Rhizoma and Corydalis Rhizoma were
ground to obtain fine powder while others ground to be
coarse powder. Cynanchi Paniculati Radix et Rhizoma
was distilled with water (1:8, w/v) for 4 h and 30% NaCl
was added into the obtained distillate to yield salt-outings.
After filtration, the residues of Cynanchi Paniculati Radix
et Rhizoma and the other nine medicinal herbs (except
Coptidis Rhizoma and Corydalis Rhizoma) were extracted
with water (1:10, w/v) twice, 1 h each, of which Scutellariae
Barabtae Herba was added post boiling. The resulting
supernatant was concentrated to a relative density (RD) of
1.20 (60°C), mixed together with the abovementioned fine
powder thoroughly, and then dried out under vacuum.
Finally, the above dry extract was blended thoroughly with
the salt-outings and an appropriate amount of microcrystal-
line cellulose to produce HZJW. The yield of HZJW extract
was 31.75% (w/w) compared with the original herbs.
Chemical profile of HZJW was analyzed by HPLC
(see Additional file 1: Figure S1). A voucher specimen
was deposited at GUCM, with the registration number20091102. HZJW was stored at 4°C and diluted to
the desired concentrations in distilled water at the
time of administration.
Bacterial strains and cultivation
Helicobacter pylori strain ATCC 43504 (Vac A and Cag
A positives) employed for the assay was obtained from
American Type Culture Collection (Rockville, MD), and
stored at −80°C in Muller–Hinton broth (OXOID)
containing 15% (w/v) glycerol until experimentation.
Frozen H. pylori isolate was thawed and grown on Brucella
agar supplemented with bovine serum albumin (BSA) for
72 h at 37°C under a microaerophilic atmosphere (85% N2,
10% CO2, 5% O2) and 98% humidity. Each plate was
swabbed with a sterile cotton-tipped applicator, and the
tested organism inocula used for the dilution tests were
prepared by suspending 72 h colonies in 2 mL of sterile
distilled water (DW) to obtain turbidity equivalent to a 2.0
McFarland standard (~108 CFU/mL).
Experimental animals and maintenance
Sprague–Dawley (SD) rats (180 ± 20 g), Balb/c mice
(18 ± 2 g), Kun-ming (KM) mice (18 ± 2 g) of both
sexes at the initiation of treatment were obtained
from the Medical Experimental Animal Center of
Guangzhou University of Chinese Medicine and Evaluation
and Research Center for Toxicology Institute of Disease
Control and Prevention PLA. Licences for rats and mice
were SCXK (YUE) 2008–0020, 2009–0210 and SCXK
(JUN)2007-004, respectively. For the experiment, the
animals were transferred for the laboratory and submitted
to adaptation by period of 7 days. They were acclimatized
under controlled temperature (25 ± 2°C) and humidity
(50-70%) on a 12-h light/12-h dark cycle (artificial
lighting from 08:00 to 20:00) and had free access to
standard chow and drinking water. In all experiments,
the animals were kept in cages with raised, wide-mesh
floors to prevent coprophagy. The experimental protocols
involved were in accordance to the rules and guidelines of
the Experimental Animal Center of Guangzhou University
of Chinese Medicine and, approved by the Animal
Care and Use Ethics Committee of our institution,
with reference to European Community guidelines for
the use of experimental animals.
Chemicals and drugs
Aspirin was obtained from Bayer HealthCare AG (Lot.
BTA8RR3), dexamethasone was obtained from Zhejiang
Xianju pharmaceutical Co., LTD (Lot. 091032);ranitidine
was purchased from O tevez (foshan) pharmaceutical
Co., LTD (Lot. 0908521); amoxicillin was from Zhuhai
federal pharmaceutical Co., LTD (Lot. 00800208).
Azithromycin was purchased from Suzhou Changzheng
Hinkay pharmaceutical Co., LTD (Lot. 100604); gentamycin
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Co., LTD (Lot. 100630950); ampicillin was obtained
from Shandong Lukang pharmaceutical Co., LTD
(Lot. L100708). Formaldehyde and phenol red were
from Guangzhou Chemical Reagent Factory (Lot.
20100302 & 20091021). Hydrochloric acid, sodium
hydroxide and alcohol were purchased from
Guangzhou chemical reagent factory (Lot. 20091014,
20090401 & 20090304). H. pylori urease Immunogold
Testing kit was from Beijing Tian Hong Sig biotech-
nology Co., Ltd (Lot. 010652); H. pylori infection test
paper (Rapid Urease Test, RUT) was from Zhuhai
Kedi science and technology development Co., Ltd
(Lot. 110401). Scutellarin (Lot. 110842–200605), ber-
berine hydrochloride (Lot. 110713–200910) and
paeonol (Lot. 110708–200505) were purchased from
National Institute of Food and Drug Control (Beijing,
China) with purity over 98% based on HPLC analysis.
HPLC-grade ethanol and acetonitril were obtained
from Honeywell (Honeywell, USA). All reagents were
at least of analytic grade and applied according to the
specific instruction manual.HCl/Ethanol-induced ulcerogenesis
The experiment was carried out according to the
method of Morimoto et al. [18], with the following
modifications. Rats of each sex were randomly divided
into five groups of ten animals each. The first group
was given 1 mL of vehicle (normal saline), and the
second group was treated with ranitidine (250 mg/kg,
p.o.). The remaining groups received 260, 520 and
1040 mg/kg (p.o.) of HZJW respectively. All the treatments
were administered daily for 3 consecutive days. All rats
were subjected to abrosia 24 h prior to the ulcerogenic
challenge. On the 4th day, one hour after the last adminis-
tration, all rats received an oral dose of 1 mL of 0.15 M
HCl in 60% ethanol to induce gastric ulcer. One hour post
ulcerogenic challenge, all animals were sacrificed by cervical
dislocation, and stomach of each rat was removed and
inflated with 10 mL of 1% buffered formalin solution to fix
for 10 min. Subsequently, each stomach was incised along
the greater curvature and rinsed with normal saline to
remove stomach contents, then the lengths of the
necrotizing lesions were measured under a dissecting
microscope, to access the formation of ulcers
(hemorrhagic lesions).The maximum length of each
lesion was determined and the sum of lengths of all
lesions (mm) for each stomach was expressed as the
ulcer index (UI), and the inhibition percentage was
calculated by the following formula:
Inhibition %ð Þ ¼ UIcontrol−UItreatð Þ=UIcontrol½   100%Nonsteroidal anti-inflammatory drug (NSAID)-induced
ulcer
The experiment was carried out according to the
method by Nwafor et al. [19] with a few modifications.
Rats of either sex were randomly divided into five groups
of ten animals each. The first group was given 1 mL of
vehicle (normal saline), and the second group was treated
with ranitidine (250 mg/kg, p.o.). The remaining groups
received 260, 520 and 1040 mg/kg (p.o.) of HZJW respect-
ively. All the treatments were administered daily for 3 con-
secutive days. All rats were subjected to fast 24 h before the
ulcerogenic challenge. On the 4th day, one hour after the
last administration, all the rats received an oral dose of as-
pirin (100 mg/kg) to induce gastric ulcer. Seven hours after
the aspirin challenge, all animals were sacrificed by cervical
dislocation, and stomach of each rat was excised and
inflated with 10 mL of 1% buffered formalin solution to fix
for 10 min. Thereafter, the greater curvature of each stom-
ach was incised, and the extent of gastric damage in the
glandular region was evaluated according to the ulcerative
lesion index and inhibition percentage as described above.
In vitro anti-H. pylori assay
Agar dilution test was employed to analyze the suscepti-
bility of reference strain H. pylori to HZJW in two-fold
serial dilution in the range of 500–0.5 mg/mL. H. pylori
were cultivated for 72 hours on blood agar, harvested
and suspended in Brucella broth at a final concentration
of 2.48 × 109 CFU/mL. Thereafter, a volume of 100 μL
bacterial suspension was inoculated in the Brucella medium
containing HZJW of serial decreasing concentrations
(500–0.5 mg/mL). In addition to the tested agent,
amoxicillin was employed as the positive control. Under
the same condition, surfaces that were inoculated with a
suspension of H. pylori without any tested materials and
non-inoculated media were used as controls. Inocula were
incubated at 37 °C under a microaerophilic atmosphere for
72 hours. Minimum inhibitory concentration (MIC), the
lowest concentration that inhibits the visible growth
of bacterium was determined. This experiment was
performed in triplicate.
In vivo anti-H. pylori assay
Balb/c mice of either sex (except the normal group that
was given normal saline) were pretreated with an oral
dose of 0.5 mL antibiotic mixture (ampicillin 10 mg/mL,
gentamicin 1.2 mg/mL, azithromycin 10 mg/mL) for 3
consective days, to make sure that they were free from
any H. pylori-like organisms that could have been
acquired through natural infection. On the 4th day, mice
were intragastricly administrated with 0.5 mL freshly
prepared suspension of H. pylori (108 CFU/mL) daily for
7 days. During this interval, mice were deprived of chew
supplement but free access to drinking water was
Xie et al. BMC Complementary and Alternative Medicine 2013, 13:119 Page 5 of 19
http://www.biomedcentral.com/1472-6882/13/119maintained for 12 h each day. On the second day following
the last inoculation, the infected animals were randomly
grouped according to the following doses: 520, 1040 and
2080 mg/kg HZJW, and were treated for 8 successive
weeks (one administration per day), while the control group
was given 20 mg/kg normal saline. Amoxicillin, suspended
in 0.5% w/v CMC, was used as reference drug, and was
administered orally to the mice for 8 successive weeks at a
dose of 670 mg/kg body weight, which was approximately
10 times of the maximum recommended human dose.
After the last administration, all mice were fasted for
24 h, blood samples were collected from retro-orbital
and sacrificed by cervical dislocation. Serum was prepared
and subjected to H. pylori urease Immunogold Testing kit
to assess H. pylori clearance. All procedures were
performed as described according to the manufacturers’
recommendation in the kit manuals.
At the same time, the stomach was excised, and the
gastric mucosa tissue was submitted to rapid urease test
(RUT). In brief, with the aid of tweezers, a fragment of
gastric tissue was inserted in the centre of a minitube
containing urease gel. Inoculation times were recorded.
The minitubes were kept at room temperature and the
colour change was evaluated within 3 min. Test result
was considered strong positive if an alkaline reaction
had developed (from yellow to dark pink within the
tissue margin) in 1 min, and weak positive if in 3min,
while negative if the colour failed to exhibit any
colour variation within 3 min in the medium (yellow
or light orange). The rest of the stomach tissues were
fixed with a 10% formalin solution, dehydrated,
embedded in paraffin, sectioned, deparaffinized, and
stained with carbolic acid and basic fuchsin for H.
pylori detection.
Acute toxicity test of HZJW
Acute oral toxicity study was performed according to
fixed dose procedure. Two experimental groups of
mice (10 mice of each sex in each group) were
treated orally with a single dose of 0 and 18.0 g/kg
body weight. Animals receiving the vehicle (saline)
served as control. Animals were observed individually
at least once during the first 30 min after administration,
periodically during the first 24 h (with special attention
during the first 4 h) and daily thereafter for a period
of 14 days. The observation principally included
changes in skin and fur, eyes and mucous membrane
(nasal), autonomic changes (salivation, lacrimation,
perspiration, piloerection, urinary volume, and defecation)
and alterations of the central nervous system (ptosis,
drowsiness, gait, tremors and convulsion). Food and
water were provided throughout the experiment. For
14 days the animals were weighed and the number of
deaths noted.Experimental schedule for general toxicity of HZJW
To generally detect potential long-term, repeat-dose
toxicity of HZJW and thereby define the characteristic,
extent, dose and time-dependent relationship, as well as
target organs and tissues of potentially toxic effects, 80
male and 80 female SD rats were assigned randomly
and evenly to 4 experimental groups. The animals
were separated by gender and housed five in each
cage. Group I animals (control) were orally administered
with distilled water throughout the course of the study.
Animals in Groups II (1000 mg/kg body weight/day), III
(2500 mg/ kg body weight/day), IV (5000 mg/kg body
weight/day) received orally administered HZJW dissolved
in distilled water once-daily for a period of 13 or 26 weeks.
The dosages selected in the present study were based on
existing data on the effective dose, results of acute toxicity
study of HZJW in mice, and suggested human dose
(equivalent to 10, 25, and 50 times of the normal human
dose in clinical prescription, respectively). Clinical
signs (general behavior, fur condition, breathing and
nose conditions, eyes and oral secretions, urine and
faeces), toxic reactions, and mortality were monitored
daily after the initiation of HZJW treatment. Body
weight, food and water consumption were recorded
once a week. After 13 weeks, 5 rats per each sex in
each group were sacrificed. Another 10 rats per each
sex in each group were sacrificed at the end of the
26th week. The remaining rats were sacrificed after 4
weeks of recovery. The animals of the recovery
groups were observed for reversibility, persistence and
delayed occurrence of toxic effects. All examinations
were conducted as described above.
At the end of the tested period, all animals were sacrificed
and subjected to hematology and clinical chemistry assays,
ophthalmic testing (cornea, conjunctiva, iris, pupil, atria,
len, fundus, eyelid), necropsy examination, organ weighing,
and histopathologic examination. This toxicity study was
carried out in compliance with the Testing Guidelines for
Safety Evaluation of Drugs (Notification [Z] GPT3-1 issued
by China Food and Drug Administration (SFDA) on
March 2005) and Good Laboratory Practice Regulations
for Nonclinical Laboratory Studies.
Clinical observation and feed consumption
The animals were observed daily prior to and following
administration for signs of toxicity and mortality through-
out the experimental period. Detailed clinical signs were
assessed and recorded, including changes in skin and fur,
eyes and mucous membranes, manure, psyche states and
behavior patterns, etc. The body weight was measured at
the initiation of treatment and once a week during the
treatment period thereafter. The amounts of feed were
weighed before they were supplied to each cage and their
remnants were measured the next day. The differences
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(g/animal/day).
Haematological and biochemical parameters
Samples of blood were obtained from all animals on
Week 13 and Week 26 of the investigation, and after
recovery. All rats were fasting but allowed access to
water ad libitum for more than 12 h prior to blood
sample collecting. Blood samples were collected into two
tubes: (1) heparinized centrifuge tubes and (2) dry non-
heparinized centrifuge tubes. The heparinized blood was
used for a hematological determination, which include red
blood cell (RBC), hemoglobin (HGB), hematocrit (HCT),
mean corpuscular volume (MCV), mean corpuscular HGB
(MCH), mean corpuscular HGB concentration (MCHC),
red cell distribution width (RDW), platelets (PLT), mean
platelet volume (MPV), platelet distribution width (PDW),
white blood cell (WBC) counts, reticulocytes (RET),
neutrophils (NE), lymphocytes (LYM), monocytes (MON),
eosinophils (EOS), and basophils (BAS) with a MEK-7222K
Hematology analyzer (Nihon Kohden, Japan) according to
the manufacturer’s operator manual. Plasma was isolated
and used to determine the prothrombin time (PT) using a
coagulometer (CA-50; Sysmex, Japan).
The non-heparinized blood was allowed to coagulate
before being centrifuged and the serum separated.
Serum was analyzed for changes in biochemistry using
an automatic biochemical analyzer (RA-1000, Technico,
USA), which measured aspartate aminotransferase activity
(AST), alanine aminotransferase activity (ALT), alkaline
phosphatase activity (ALP), albumin (ALB), total protein
(TP), total cholesterol (CHOL), creatine phosphokinase
activity (CPK), total bilirubin (T-BIL), direct bilirubin
(D-BIL), creatinine (Cre), triglycerides (TG), urea
(Ure) and glucose (GLU). The concentrations of sodium
ions (Na+), potassium ions (K+) and chloride ions (Cl-)
were measured with an electrolyte autoanalyzer (EasyLyte
Na+/K+/Cl- Analyzer, MEDICA, USA). All parameters of
blood chemistry and hematology were measured following
standard procedures.
Organ weights, gross necropsy and histopathological
examination
All animals were fasted overnight before scheduled
necropsies. A complete necropsy was conducted on
all animals and consisted of an external examination,
including the identification of all clinically recorded lesions,
and a detailed internal examination. The rats were anesthe-
tized with diethyl ether and sacrificed by decapitation after
blood collection from the abdominal aorta. After dissection
to remove fat and connective tissue, the following organs
were carefully dissected out and weighed: brain (cerebrum,
cerecellum and brainstem), thymus glands, heart, lungs,
liver, spleen, kidneys, adrenal glands, testis/ovary andepididymis/uterus. The relative organ weight was calculated
based on the terminal body weight before fixation.
The following organs of all animals were fixed in 10%
neutral formalin: brain, thoracic spinal cord, thyroid
glands, Gley's glands, pituitary gland, thymus, adrenal
glands, esophagus, salivary glands, stomach, small intestine
(duodenum, jejunum and ileum), large intestine (cecum,
colon and rectum), pancreas, spleen, lungs, trachea,
kidneys, liver, heart, aorta, bladder, testes, epididymides,
ovaries, uterus, prostate gland, vagina, mammary gland,
sciatic nerve, urinary mesenteric lymph node, sternum,
sub-mandibular lymph nodes, bone marrow.
The fixed organs of the vehicle control and high dose
group and any organs from the other groups that displayed
gross abnormalities were subjected to histopathological
examination. These samples were Paraffin-embedded,
microsectioned at a nominal thickness of 4 μm and then
stained with hematoxylin and eosin for histopathological
examination.Statistical analysis
The data obtained by the various parameters was
statistically evaluated by one way analysis of variance
(ANOVA), and presented as means ± standard deviation
(S.D.) for the indicated number of independently
performed experiments. The body and organ weight,
food and water consumption, hematological parameters,
and blood biochemical parameters were analyzed for
homogeneity of dispersion by ANOVA. The parameters
found to be significant in ANOVA were assessed by the
Dunnett test. Significant differences (as shown in the
plots) were classified as: * for P < 0.05; more significant
** for P < 0.01.Results
Effect of HZJW on HCl/Ethanol-induced gastric ulcer
Ulcerative indices and gastroprotection percentage were
determined in rats with HCl/Ethanol-induced ulcers by
measuring ulcerative lesion length. As shown in Figure 1,
intragastric administration of HCl/Ethanol to rats
caused severe gastric mucosal damage (in the form of
hemorrhagic streaks), while administration of HZJW
displayed statistically significant anti-ulcerogenic activity,
and dose-dependently reduced the ulcerative lesion
index (116.70 ± 36.4; 102.20 ± 18.20, P < 0.05; 84.10 ± 12.1,
P < 0.01 at doses of 260, 520 and 1040 mg/kg,
respectively), as compared with the model group
(134.10 ± 31.69). Ranitidine also offered significant
protection against HCl/Ethanol-induced gastric lesions
(20.40 ± 6.93, P < 0.01). The percentages of ulcer
inhibition were 12.98%, 23.79%, 37.29% and 45.04% for
the groups treated with 260, 520 and 1040 mg/kg of
HZJW and ranitidine, respectively.
Figure 1 Protective effect of HZJW and raniditine on ulcerative lesion induced by HCl/Ethanol. (A) Ulcerative lesion index; (B) Ulcer
inhibition (%). Vehicle group (Open column), ranitidine group (250 mg/kg/d, grey bar), HZJW groups (260, 520, and 1040 mg/kg/d, dark bars).
Vertical bars represent standard deviation (S.D.), where n = 10. Asterisks designate significant differences: *P < 0.05 & **P < 0.01 vs. Vehicle group.
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To further verify the cytoprotective mechanism of HZJW
against gastric ulcer, NSAIDs-induced mucosal damage
model was employed. It was observed that aspirin
produced extensive necrosis of the gastric mucosa, whereas
animals treated with HZJW (260, 520 and 1040 mg/kg)
exhibited potent protection against aspirin-induced
gastric ulceration in a dose-dependent manner. Orally
applied HZJW significantly reduced the ulcer lesion
index (35.40 ± 5.93; 31.30 ± 8.08, P < 0.05; 26.80 ± 8.27,
P < 0.01) respectively, as compared to control group
(41.60 ± 10.80). As well, ranitidine conferred prominent
protection against ulcerogenesis (20.40 ± 6.93, P < 0.01).
The extent of inhibitions for the respective doses employed
was 14.90, 24.76, 35.58 and 50.96%, respectively. These
results were summarized in Figure 2.In vitro anti-H. pylori assay
The agar dilution method has been standardized as the
reference method for minimum inhibitory concentration
(MIC) determinations by the Clinical And LaboratoryFigure 2 Protective effect of HZJW and raniditine on ulcerative lesion
(%). Vehicle group (Open column), ranitidine group (250 mg/kg/d, grey bar
represent standard deviation (S.D.), where n = 10. Asterisks designate signifiStandards Institute (CLSI). In the in vitro assay, MICs for
HZJW and amoxicillin (positive control) were 125 and 0.12
μg/mL respectively. The in vitro anti-H. pylori potency of
amoxicillin was far more pronounced than that of HZJW.In vivo anti-H. pylori assay
Taking into consideration these data as well as the
limitations of in vitro efficacy experimentation, we
also evaluated the in vivo eradication potency of
HZJW in previously described rapid screening mouse
model [20]. In the rapid urease assay, all animals in
control group were negative for urease reaction, whereas in
H. pylori-inoculated group 50% were positive. Treatment
with HZJW (520, 1040 and 2080 mg/kg) increased
the negativity of the urease test in a dose-related
manner, reaching 83.33% (P < 0.01), 76.5% and 72.2%
(P < 0.05) respectively, in parallel to model animals. The
test negativity rate was more prominent with HZJW
treatment of lower dose. For the group given standard
treatment--amoxicillin, negativity was 88.24% (P < 0.01),
as shown in Figure 3A.induced by NSAID. (A) Ulcerative lesion index; (B) Ulcer inhibition
), HZJW groups (260, 520, and 1040 mg/kg/d, dark bars). Vertical bars
cant differences: *P < 0.05 & **P < 0.01 vs. Vehicle group.
Figure 3 Effect of HZJW and amoxicillin on the eradication of Helicobacter pylori via rapid urease test (A), immunogold test (B) and
histopathological analysis (C). Vehicle group (Open column), amoxicillin group (670 mg/kg/d, grey bar), HZJW groups (520, 1040 and
2080 mg/kg/d, dark bars). *P < 0.05 & **P < 0.01 vs. Vehicle group.
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(Figure 3B), the infection rate for animals treated
with HZJW of 520, 1040 and 2080 mg/kg was 17.65%
(P < 0.01), 33.33% (P < 0.05) and 17.65% (P < 0.01) res-
pectively, as compared with 68.75% of the model counter-
part. The group treated with amoxicillin showed better
results, in general, than those groups receiving HZJW
with incidence rate of 11.76% (P < 0.01).
In relation to the presence of H. pylori in gastric
mucosa, HZJW treatment depleted the number of viable
H. pylori in gastric tissues of inoculated animals. According
to the data obtained (Figure 3C), it was verified that those
groups treated with 520, 1040 and 2080 mg/kg of
HZJW presented a dose-dependent decrease in positive
cases with carbolic acid & basic fuchsin staining, by
66.67% (P < 0.05), 41.18% (P < 0.001) and 11.11% (P < 0.01)
respectively. Treatment with standard drugs caused
complete elimination of H. pylori.Acute toxicity evaluation
The acute dose study provides a guideline for selecting
doses for the subacute and chronic low-dose study, which
may be more clinically relevant [21]. In the acute toxicity
study, the oral LD50 of HZJW was over 18.0 g/kg by a
single oral administration following fixed dose procedure.
Animals did not manifest significant abnormal signsand alternations, behavioral changes, water or food
consumption, body weight changes, or macroscopic
findings at any time of observation. Autopsy results
exhibited no significant change or lesion in the viscera of
any animal.
Survival and clinical signs
In the chronic oral toxicity assessment,animals treated
with doses of 5000,2500 and 1000 mg/kg (equivalent to
50-, 25- and 10-fold human clinical doses, respectively)
was observed after 26 weeks of daily administration of
HZJW, as well as after the 4-week recovery period.
No drug-related deaths were observed in any of the
HZJW-treated groups. Six rats of both sexes experienced
slight fur loss and the region of hair loss was limited on
grasping area including shoulder and back neck and just
partial loss. The symptom disappeared after certain period.
No other test-article-related clinical signs were observed in
rats dosed up to 5000 mg/kg with HZJW. No abnormal
findings were observed during the ophthalmological
examination in any of the groups (data not shown).
Body weights, organ weights and feed consumption
In all groups, body weight gradually increased for 6 months,
and changes in body weight in HZJW treated groups
relative to the control group were not significant during the
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gained weight with time. From the 1st week to the
30th week, body weight of animals in three treatment
group showed no significant differences compared
with that of control. No statistically significant differences
in food (Figure 5) consumption were detected between
the control and treatment group regardless of sex or
recovery group. Absolute and relative organ weights
of 26-week treated rats are shown in Table 2. Since
these changes in organ weight by the end of week 26
and recovery were not accompanied by any relevant
histopathological change. The organ weight changes
were not considered to be of toxicological significance
by HZJW treatment.Hematological parameters
Hematopoietic indices have been reported to be very
sensitive to toxic compounds and serve as important
index of physiologic and pathologic status for both
animals and humans [22]. The effect of HZJW on the
hematological parameters of the experimental and
control rats is presented in Table 3. The results indicated
that all hematological parameters measured remained
within the physiological range throughout the 30-week
experimental period. There were no significant changes in
mean corpuscular volume, red cell distribution width,
platelets, platelet distribution width, prothrombin time,
eosinophils, basophils, monocytes, and reticulocytes
values between the control and treated animals (main
groups). Despite a significant change was observed in some
parameters (hemoglobin, mean corpuscular hemoglobin,
mean corpuscular hemoglobin concentration, mean platelet
volume, white blood cell, lymphocytes, neutrophils),
the above parameters remained within the range of
normal physiological variation and there was no dose
response relationship.Figure 4 Mean body weight of male (A) and female (B) rats dosed wiBlood biochemistry
The data for the biochemical parameters in the treated and
control rats are presented in Table 4. All the parameters
remained within the physiological range throughout the
30-week experimental period. No statistically significant
differences were observed amongst the blood chemistry,
including alkaline phosphatase activity, total cholesterol,
urea, creatine phosphokinase activity, sodium ions,
potassium ions and chlorideions between the control
and treated animals. Despite some parameters experienced
significant variation (glucose, triglycerides, aspartate amino-
transferase activity, alanine aminotransferase activity, total
protein, total bilirubin, direct bilirubin, alkaline phosphatase
activity, albumin and urea), there were no dose response
relationships and all of above parameters remained within
the physiological range.Histopathogical findings
Histopathological examinations are an important aspect of
safety assessments. In the histopathological examination, no
noteworthy HZJW related lesions were observed, though
some abnormalities were found. The major pathological
findings from the histopathological examination included
minimal inflammatory cell foci and vacuolar degeneration
in the liver, portal myocardial inflammatory cell infiltration
in the heart, peri-bronchovascular chronic inflammation
and, inflammatory cell foci hyperplasia in the lungs, the
tubule interstitial chronic inflammation, tubule cortical
vacuolar degeneration and protein cast in the kidneys.
However, these symptoms are part of chronic progressive
nephropathy often observed in rats of old age and is
particularly frequently observed in males. These findings
were noted in both sexes in a manner not dependent on
dose. The high-dose group (5000 mg/kg) did not differ
significantly from the control group in any organ. These
changes were not considered to be treatment related,th HZJW.
Figure 5 Mean food consumption by male (A) and female (B) rats treated with HZJW.
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observed in untreated old rats.
Discussion
Currently, the commercial use of traditional herbal
medicines has increased and various new drugs are
being developed based on this development. Concerns
have been raised over the lack of scientific evidence
regarding the efficacy and safety of herbal products
[23,24], though some have been verified by clinical
trials. Many researchers have undertaken studies to
validate the efficacy of herbal prescriptions; however,
few have initiated investigations addressing their safety
and toxicity. Indeed, the toxicity of many of these herbal
remedies has not been scientifically validated, and their
safeties have been questioned recently due to reports
of side effects and fatalities [25], hepatotoxicity [26],
and nephrotoxicity [27]. Considering the complexity
of general herbal prescriptions and their inherent biological
variation, it is necessary to evaluate their safety, efficacy,
and quality [28]. In this study, we examined the effi-
cacy and safety of HZJW, an herbal-derived anti-ulcer
formulation applied in clinics, via gastroprotective
assessment, anti-H. pylori assay, oral acute toxicity and a
systemic 6-month repeated-dose toxicity study.
The gastroprotective effect of HZJW was investigated
by two animal models of acute gastric injury induced by
necrotizing agents, i.e., HCl/Ethanol and NSAIDs. The
HCl/Ethanol method is a rapid and convenient way of
screening agents of antiulcer potency, which is assessed
in terms of absence or reduction in macroscopically
visible lesions [29]. HCl/Ethanol acts by exerting a direct
toxic effect on the epithelium, inducing the formation of
characteristic necrotic lesions due to a reduction in the
mucus. Besides, it causes reduction of gastric blood
flow, solubilization of mucus and bicarbonate secretion
[30]. HCl/Ethanol induced gastric damage ranging fromendothelial microvascular damage to development of
macroscopic gastric mucosal lesions, which can be mainly
attributed to the inhibition of cytoprotective prostaglandins
(PG) biosynthesis [31]. A number of mechanisms that
include enhanced gastric mucosal defense through increas-
ing mucus and/or bicarbonate production, reducing gastric
acid secretion or by simply neutralizing the gastric acidity
[32], can mediate the gastric mucosal protection
against HCl/Ethanol. In the present study, the control
group subjected to HCl/Ethanol clearly produced the
expected characteristic zone of necrotizing mucosal
lesions, while pretreatment with HZJW had significantly
and dose-dependently decreased the ulcerative index and
the percentage of lesion, thus markedly improved
ulcer healing. These results indicated that HZJW
exhibited protective effect against HCl/Ethanol-induced
ulcerogenesis in rats.
Another experimental protocol employed in the
investigation was NSAIDs- induced ulcer by aspirin,
which induced gastric lesions due to the distinct
mechanism in generating ulcer lesions compared
with HCl/Ethanol. NSAIDs induce injury/bleeding
via three key pathways: inhibition of cyclooxygenase
(COX)-1 activity, inhibition of COX-2 activity, and
direct cytotoxic effects on the epithelium [33]. The
main importance of the systemic effects of NSAIDs,
in terms of inducing gastric ulceration, is their ability to
suppress prostaglandin synthesis [34]. In the stomach,
prostaglandins play an important protective role by
stimulating the secretion of bicarbonate and mucus,
maintaining the blood flow of the mucosa, and they are
responsible for regulating mucosal cell renewal [35].
Aspirin is a cyclooxygenase inhibitor which suppresses gas-
troduodenal bicarbonate secretion, reduces endogeneous
prostaglandin biosynthesis and disrupts the mucosal barrier
as well as mucosal blood flow in animals, causing
increased susceptibility to gastric mucosal lesions [36]. In
Table 2 Absolute & relative organ weights in rats orally treated with HZJW
Parameter Sex
Dose (mg/kg)
0 mg/kg 1000 mg/kg 2500 mg/kg 5000 mg/kg
13 wk 26 wk Recovery 13 wk 26 wk Recovery 13 wk 26 wk Recovery 13wk 26 wk Recovery
Body
weight
Male 486.2 ± 16.4 604.4 ± 70.0 641.3 ± 95.7 516.3 ± 101.3 634.6 ± 60.1 670.7 ± 65.7 482.3 ± 44.4 628.1 ± 67.7 660.4 ± 39.7 481.8 ± 39.5 637.8 ± 82.5 691.7 ± 63.8
Female 291.3 ± 16.8 331.8 ± 27.2 338.9 ± 35.6 280.9 ± 17.0 333.4 ± 32.2 329.7 ± 34.7 266.0 ± 9.3 308.3 ± 25.7 318.4 ± 15.2 269.0 ± 36.4 322.2 ± 31.9 336.6 ± 29.5
Brain Male 2.096 ± 0.064 2.240 ± 0.124 2.163 ± 0.103 2.214 ± 0.115 2.221 ± 0.095 2.191 ± 0.090 2.080 ± 0.117 2.281 ± 0.079 2.224 ± 0.092 2.092 ± 0.183 2.238 ± 0.089 2.261 ± 0.049
Female 1.996 ± 0.066 2.021 ± 0.064 2.088 ± 0.096 1.947 ± 0.040 2.011 ± 0.064 2.028 ± 0.043 2.006 ± 0.046 2.008 ± 0.105 2.003 ± 0.063 1.985 ± 0.029 2.040 ± 0.060 2.029 ± 0.039
% to body
weight
Male 0.431 ± .016 0.376 ± 0.054 0.344 ± 0.055 0.439 ± 0.067 0.352 ± 0.033 0.329 ± 0.034 0.434 ± 0.039 0.366 ± 0.036 0.338 ± 0.027 0.436 ± 0.043 0.356 ± 0.046 0.329 ± 0.030
Female 0.687 ± 0.041 0.612 ± 0.041 0.621 ± 0.066 0.695 ± 0.045 0.608 ± 0.060 0.620 ± 0.065 0.754 ± 0.023* 0.655 ± 0.057 0.630 ± 0.019 0.747 ± 0.082 0.638 ± 0.065 0.606 ± 0.051
Thymus Male 0.297 ± 0.097 0.270 ± 0.069 0.262 ± 0.063 0.351 ± 0.170 0.219 ± 0.106 0.250 ± 0.092 0.313 ± 0.043 0.223 ± 0.084 0.200 ± 0.038 0.270 ± 0.048 0.262 ± 0.056 0.224 ± 0.059
Female 0.367 ± 0.057 0.245 ± 0.073 0.187 ± 0.057 0.325 ± 0.041 0.232 ± 0.038 0.225 ± 0.045 0.283 ± 0.053 0.226 ± 0.061 0.214 ± 0.071 0.304 ± 0.091 0.231 ± 0.063 0.218 ± 0.023
% to body
weight
Male 0.061 ± 0.018 0.044 ± 0.009 0.041 ± 0.008 0.065 ± 0.019 0.034 ± 0.013* 0.037 ± 0.013 0.065 ± 0.011 0.035 ± 0.012 0.030 ± 0.005* 0.056 ± 0.008 0.041 ± 0.008 0.032 ± 0.006
Female 0.126 ± 0.017 0.074 ± 0.023 0.055 ± 0.014 0.116 ± 0.015 0.070 ± 0.010 0.069 ± 0.015 0.106 ± 0.018 0.073 ± 0.017 0.067 ± 0.021 0.112 ± 0.026 0.071 ± 0.014 0.065 ± 0.009
Heart Male 1.381 ± 0.111 1.625 ± 0.204 1.653 ± 0.259 1.494 ± 0.193 1.710 ± 0.229 1.613 ± 0.225 1.408 ± 0.156 1.702 ± 0.169 1.749 ± 0.138 1.467 ± 0.093 1.699 ± 0.182 1.912 ± 0.182
Female 0.832 ± 0.042 1.100 ± 0.101 1.046 ± 0.138 0.917 ± 0.094 1.089 ± 0.109 1.013 ± 0.091 0.905 ± 0.066 1.024 ± 0.091 0.986 ± 0.069 0.969 ± 0.102 1.098 ± 0.136 1.014 ± 0.068
% to body
weight
Male 0.284 ± 0.014 0.270 ± 0.029 0.258 ± 0.004 0.294 ± 0.037 0.271 ± 0.039 0.240 ± 0.015* 0.292 ± 0.021 0.272 ± 0.021 0.265 ± 0.020 0.306 ± 0.028 0.268 ± 0.016 0.277 ± 0.016
Female 0.286 ± 0.012 0.333 ± 0.034 0.308 ± 0.010 0.326 ± 0.023* 0.328 ± 0.027 0.308 ± 0.016 0.341 ± 0.036* 0.334 ± 0.044 0.310 ± 0.016 0.362±0.025** 0.341 ± 0.032 0.302 ± 0.018
Lung Male 1.782 ± 0.201 1.831 ± 0.271 1.845 ± 0.237 1.862 ± 0.779 1.876 ± 0.246 1.910 ± 0.094 1.528 ± 0.103* 1.930 ± 0.088 1.916 ± 0.052 1.516 ± 0.066* 1.898 ± 0.127 2.099 ± 0.322
Female 1.210 ± 0.061 1.434 ± 0.110 1.409 ± 0.098 1.506 ± 0.538 1.449 ± 0.168 1.28 ± 0.062* 1.210 ± 0.072 1.438 ± 0.166 1.419 ± 0.048 1.204 ± 0.192 1.443 ± 0.138 1.503 ± 0.152
% to body
weight
Male 0.366 ± 0.038 0.304 ± 0.041 0.289 ± 0.025 0.354 ± 0.087 0.296 ± 0.034 0.287 ± 0.033 0.318 ± 0.021* 0.310 ± 0.029 0.291 ± 0.016 0.316 ± 0.026 0.300 ± 0.028 0.303 ± 0.035
Female 0.416 ± 0.024 0.434 ± 0.036 0.418 ± 0.043 0.537 ± 0.189 0.438 ± 0.064 0.394 ± 0.041 0.456 ± 0.037 0.466 ± 0.036 0.446 ± 0.025 0.447 ± 0.021 0.450 ± 0.048 0.448 ± 0.041
Liver Male 11.492 ± 1.894 12.852±1.753 14.019±2.841 12.564±3.570 13.450±1.903 14.001±1.859 11.882 ± 1.267 14.860 ± 2.256* 15.212 ± 1.286 11.380± 0.892 16.043 ± 3.106* 16.306 ± 1.798
Female 6.885 ± 0.495 8.213 ± 1.184 7.582 ± 0.862 7.057 ± 0.719 8.522 ± 0.984 7.761 ± 1.048 6.920 ± 0.305 8.136 ± 0.742 7.659 ± 0.794 7.356 ± 1.218 8.733 ± 0.742 7.594 ± 0.724
% to body
weight
Male 2.356 ± 0.312 2.125 ± 0.125 2.180 ± 0.190 2.407 ± 0.256 2.117 ± 0.187 2.084 ± 0.143 2.461 ± 0.062 2.363±0.209** 2.301 ± 0.061 2.366 ± 0.123 2.498±0.193** 2.357 ± 0.164
Female 2.369 ± 0.223 2.481 ± 0.355 2.239 ± 0.151 2.510 ± 0.189 2.561 ± 0.237 2.351 ± 0.132 2.605 ± 0.169 2.644 ± 0.205 2.402 ± 0.171 2.728 ± 0.105* 2.728 ± 0.300 2.258 ± 0.159
Spleen Male 0.614 ± 0.042 0.799 ± 0.116 0.833 ± 0.115 0.639 ± 0.105 0.849 ± 0.110 0.795 ± 0.096 0.708 ± 0.166 0.810 ± 0.115 0.868 ± 0.133 0.673 ± 0.073 0.916 ± 0.101* 0.859 ± 0.104
Female 0.431 ± 0.023 0.618 ± 0.149 0.582 ± 0.108 0.460 ± 0.054 0.544 ± 0.074 0.553 ± 0.060 0.478 ± 0.035 0.574 ± 0.115 0.545 ± 0.035 0.446 ± 0.081 0.518 ± 0.080 0.543 ± 0.057
% to body
weight
Male 0.126 ± 0.006 0.133 ± 0.022 0.130 ± 0.009 0.126 ± 0.021 0.134 ± 0.009 0.118 ± 0.007 0.147 ± 0.030 0.129 ± 0.009 0.131 ± 0.018 0.140 ± 0.015 0.145 ± 0.015 0.124 ± 0.009
Female 0.148 ± 0.009 0.187 ± 0.046 0.172 ± 0.026 0.164 ± 0.020 0.164 ± 0.021 0.168 ± 0.013 0.180±0.016** 0.186 ± 0.033 0.171 ± 0.006 0.167 ± 0.028 0.162 ± 0.026 0.162 ± 0.018
Kidney Male 2.832 ± 0.228 3.343 ± 0.322 3.406 ± 0.309 2.943 ± 0.433 3.421 ± 0.481 3.449 ± 0.451 2.766 ± 0.141 3.519 ± 0.316 3.856 ± 0.456 3.013 ± 0.428 3.622 ± 0.410 4.178 ± 0.503*
Female 1.655 ± 0.139 1.896 ± 0.164 1.868 ± 0.199 1.568 ± 0.152 1.932 ± 0.175 1.914 ± 0.255 1.605 ± 0.045 1.978 ± 0.175 1.892 ± 0.111 1.626 ± 0.192 2.025 ± 0.164 1.857 ± 0.167
% to body
weight
Male 0.582 ± 0.031 0.557 ± 0.056 0.537 ± 0.060 0.577 ± 0.070 0.540 ± 0.072 0.513 ± 0.029 0.577 ± 0.058 0.563 ± 0.048 0.584 ± 0.062 0.624 ± 0.059 0.572 ± 0.059 0.603 ± 0.026
























Table 2 Absolute & relative organ weights in rats orally treated with HZJW (Continued)
Adrenal
grand
Male 0.068 ± 0.012 0.050 ± 0.006 0.062 ± 0.009 0.059 ± 0.013 0.056 ± 0.007 0.051 ± 0.005* 0.062 ± 0.012 0.055 ± 0.009 0.057 ± 0.005 0.053 ± 0.009* 0.056 ± 0.008 0.065 ± 0.010
Female 0.066 ± 0.007 0.063 ± 0.009 0.067 ± 0.009 0.061 ± 0.009 0.063 ± 0.008 0.055 ± 0.006* 0.066 ± 0.006 0.065 ± 0.012 0.064 ± 0.011 0.061 ± 0.008 0.069 ± 0.009 0.057 ± 0.010
% to body
weight
Male 0.014 ± 0.002 0.008 ± 0.002 0.010 ± 0.001 0.012 ± 0.004 0.009 ± 0.001 0.008 ± 0.001* 0.013 ± 0.003 0.009 ± 0.002 0.009 ± 0.001 0.011 ± 0.002 0.009 ± 0.002 0.009 ± 0.001
Female 0.023 ± 0.002 0.019 ± 0.003 0.020 ± 0.002 0.022 ± 0.003 0.019 ± 0.003 0.017 ± 0.001* 0.025 ± 0.003 0.021 ± 0.004 0.020 ± 0.004 0.023 ± 0.004 0.022 ± 0.003 0.017 ± 0.003
Testis(Rt.)/
Ovary (Lt.)
Male 3.391 ± 0.243 3.669 ± 0.398 3.767 ± 0.306 3.607 ± 0.142 3.606 ± 0.788 3.666 ± 0.315 3.324 ± 0.689 3.831 ± 0.472 3.822 ± 0.331 3.594 ± 0.362 3.632 ± 0.851 4.047 ± 0.343
Female 3.594 ± 0.362 0.146 ± 0.030 0.164 ± 0.049 0.145 ± 0.017 0.157 ± 0.038 0.157 ± 0.047 0.149 ± 0.017 0.156 ± 0.022 0.152 ± 0.016 0.148 ± 0.018 0.166 ± 0.036 0.164 ± 0.017
% to body
weight
Male 0.698 ± 0.052 0.610 ± 0.054 0.593 ± 0.050 0.716 ± 0.109 0.567 ± 0.109 0.548 ± 0.033 0.684 ± 0.095 0.613 ± 0.079 0.579 ± 0.032 0.751 ± 0.114 0.571 ± 0.128 0.587 ± 0.046
Female 0.046 ± 0.007 0.044 ± 0.010 0.048 ± 0.014 0.051 ± 0.005* 0.048 ± 0.013 0.049 ± 0.015 0.056 ± 0.007* 0.051 ± 0.006 0.048 ± 0.006 0.055 ± 0.002 0.052 ± 0.010 0.049 ± 0.006
Epididymis
(Lt.)/Uterus
Male 1.264 ± 0.099 1.542 ± 0.205 1.555 ± 0.142 1.440 ± 0.207 1.547 ± 0.329 1.562 ± 0.403 1.322 ± 0.170 1.550 ± 0.306 1.575 ± 0.170 1.431 ± 0.080* 1.511 ± 0.271 1.669 ± 0.262
Female 0.649 ± 0.173 0.803 ± 0.289 0.883 ± 0.114 0.879 ± 0.283 0.991 ± 0.340 0.970 ± 0.274 0.715 ± 0.195 0.907 ± 0.213 0.691 ± 0.152 0.752 ± 0.338 0.770 ± 0.264 0.893 ± 0.365
% to body
weight
Male 0.260 ± 0.021 0.260 ± 0.054 0.245 ± 0.026 0.285 ± 0.050 0.244 ± 0.047 0.231 ± 0.043 0.273 ± 0.015 0.248 ± 0.050 0.239 ± 0.032 0.299 ± 0.035 0.240 ± 0.053 0.241 ± 0.029
Female 0.225 ± 0.070 0.245 ± 0.092 0.264 ± 0.048 0.315 ± 0.108 0.299 ± 0.102 0.296 ± 0.084 0.269 ± 0.074 0.298 ± 0.082 0.217 ± 0.044 0.272 ± 0.084 0.240 ± 0.082 0.271 ± 0.125
Note: Data represents body weights right before necropsy, after fasting; Values are mean ± S.D. (n = 5 (4 weeks or recovery), 10 (26 weeks), recovery (30 weeks)/sex/dose).
























Table 3 Hematological values in rats orally treated with HZJW
Parameter unit sex
Hematological values
0 mg/kg 1000 mg/kg 2500 mg/kg 5000 mg/kg
13 wk 26 wk Recovery 13 wk 26 wk Recovery 13 wk 26 wk Recovery 13wk 26 wk Recovery
RBC 1012/L Male 9.18 ± 0.31 8.86 ± 0.47 8.65 ± 0.32 9.04 ± 0.33 8.72 ± 0.40 8.83 ± 0.45 9.27 ± 0.29 8.21 ± 0.71 8.48 ± 0.35 8.99 ± 0.80 8.94 ± 0.50 9.07 ± 0.71
Female 8.11 ± 0.28 7.90 ± 0.49 7.59 ± 0.55 8.30 ± 0.28 7.85 ± 0.69 8.01 ± 0.72 8.37 ± 0.79 7.84 ± 0.49 7.65 ± 0.41 8.58 ± 0.66 6.96 ± 1.47 7.90 ± 0.55
HGB g/L Male 174 ± 6 168 ± 6 170 ± 7 164 ± 7 166 ± 3 166 ± 3 171 ± 5 157 ± 11** 163 ± 5 168 ± 6 162 ± 6* 174 ± 8
Female 158 ± 2 162 ± 7 159 ± 10 163 ± 4 156 ± 12 167 ± 11 166 ± 10 155 ± 8 160 ± 10 166 ± 12 137 ± 29* 162 ± 4
HCT % Male 45.3 ± 1.3 43.7 ± 1.8 44.1 ± 1.8 43.9 ± 1.2 44.1 ± 1.1 43.3 ± 0.9 44.9 ± 1.3 42.2 ± 3.2 43.0 ± 1.4 44.4 ± 2.5 45.0 ± 2.4 46.5 ± 2.4
Female 40.8 ± 1.2 42.2 ± 2.3 40.7 ± 2.8 41.9 ± 1.2 41.6 ± 2.9 44.3 ± 3.1 42.2 ± 3.3 41.7 ± 2.4 41.0 ± 3.0 42.7 ± 2.6 37.8 ± 7.8 41.0 ± 1.7
MCV fL Male 49.3 ± 0.7 49.3 ± 1.2 51.0 ± 1.9 48.6 ± 1.7 50.6 ± 1.5 49.1 ± 1.6 48.4 ± 0.8 51.5 ± 1.8 50.7 ± 2.1 49.6 ± 3.3 50.3 ± 1.7 51.4 ± 1.5
Female 50.3 ± 1.4 53.5 ± 1.3 53.7 ± 2.4 50.5 ± 1.7 53.0 ± 1.7 55.4 ± 1.5 50.4 ± 0.9 53.2 ± 1.7 53.6 ± 1.3 49.8 ± 1.1 54.4 ± 1.6 52.0 ± 1.7
MCH pg Male 19.0 ± 0.2 19.0 ± 0.6 19.7 ± 0.8 18.1 ± 0.5 19.1 ± 0.7 18.8 ± 0.9 18.4 ± 0.3 19.1 ± 0.9 19.3 ± 0.7 18.8 ± 1.4 18.1 ± 0.7* 19.2 ± 0.7
Female 19.5 ± 0.7 20.6 ± 0.5 21.0 ± 0.8 19.7 ± 0.6 19.9 ± 0.7** 20.9 ± 0.8 19.9 ± 0.9 19.8 ± 0.6* 20.9 ± 0.5 19.4 ± 1.0 19.7 ± 0.9** 20.6 ± 0.9
MCHC g/L Male 385 ± 6 385 ± 7 386 ± 9 373 ± 9 376 ± 7* 383 ± 6 381 ± 4 371 ± 13* 380 ± 5 378 ± 10 361 ± 8* 374 ± 4*
Female 387 ± 8 385 ± 6 391 ± 8 389 ± 3 376 ± 7* 378 ± 8 395 ± 12 373 ± 6* 389 ± 8 389 ± 17 362 ± 16* 395 ± 7
RDW % Male 13.6 ± 0.5 13.3 ± 0.5 13.5 ± 0.4 13.7 ± 0.2 13.3 ± 0.3 13.4 ± 0.3 13.5 ± 0.3 13.3 ± 0.5 13.4 ± 0.5 13.7 ± 0.3 13.4 ± 0.4 13.4 ± 0.7
Female 13.1 ± 0.3 12.8 ± 0.3 12.6 ± 0.3 13.0 ± 0.3 12.7 ± 0.3 12.5 ± 0.2 12.9 ± 0.3 12.6 ± 0.3 12.9 ± 0.2 12.8 ± 0.3 13.0 ± 0.4 12.6 ± 0.5
PLT 109/L Male 823 ± 87 906 ± 48 881 ± 107 797 ± 106 831 ± 71 906 ± 76 816 ± 39 819 ± 74 872 ± 42 795 ± 30 854 ± 69 940 ± 99
Female 763 ± 55 756 ± 98 828 ± 60 859 ± 122 816 ± 62 936 ± 72 810 ± 45 792 ± 94 839 ± 91 848 ± 86 696 ± 271 865 ± 76
MPV fL Male 3.3 ± 0.4 3.7 ± 0.5 4.2 ± 0.7 3.3 ± 0.4 3.7 ± 0.4 4.2 ± 0.4 3.4 ± 0.4 3.9 ± 0.5 4.2 ± 0.4 3.5 ± 0.4 4.7 ± 0.5** 4.5 ± 0.6
Female 3.4 ± 0.4 3.7 ± 0.5 4.1 ± 0.9 3.4 ± 0.4 4.0 ± 0.5 4.5 ± 0.2 3.5 ± 0.2 4.0 ± 0.6 4.4 ± 0.5 3.5 ± 0.4 4.6 ± 1.6 4.0 ± 0.2
PDW % Male 14.8 ± 0.5 14.4 ± 0.3 14.3 ± 0.6 15.3 ± 0.4 14.3 ± 0.6 13.9 ± 0.2 14.9 ± 0.5 14.3 ± 0.4 14.4 ± 0.5 15.2 ± 1.0 14.3 ± 0.4 14.6 ± 0.6
Female 15.0 ± 0.5 14.7 ± 0.3 14.4 ± 0.6 14.9 ± 0.4 14.7 ± 0.4 15.1 ± 0.8 15.3 ± 0.8 14.6 ± 0.6 14.5 ± 0.7 15.3 ± 0.6 15.2 ± 1.9 14.1 ± 0.2
PT s Male 14.4 ± 1.8 19.0 ± 5.8 15.1 ± 0.9 18.1 ± 3.9 17.1 ± 4.4 15.1 ± 0.4 13.5 ± 0.4 15.2 ± 3.2 14.7 ± 0.4 15.2 ± 2.6 15.7 ± 3.4 14.5 ± 0.6
Female 12.7 ± 0.6 13.4 ± 0.6 14.5 ± 0.5 12.4 ± 0.5 13.3 ± 0.5 14.4 ± 0.6 12.5 ± 0.3 13.7 ± 0.7 13.9 ± 0.5 12.5 ± 0.8 13.2 ± 1.0 14.1 ± 1.2
WBC 109/L Male 6.4 ± 0.4 4.6 ± 1.1 4.7 ± 1.6 8.5 ± 3.4 6.6 ± 1.2** 5.2 ± 2.1 10.5 ± 2.7** 6.1 ± 2.3 5.2 ± 0.9 11.9 ± 2.2* 6.5 ± 2.2* 5.5 ± 1.2
Female 4.3 ± 1.2 3.1 ± 0.9 2.3 ± 0.6 6.0 ± 1.4 2.8 ± 0.8 2.4 ± 0.5 6.6 ± 2.5 3.1 ± 0.8 2.3 ± 0.6 6.9 ± 1.3 2.7 ± 1.2 2.7 ± 0.6
LYM 109/L Male 5.0 ± 0.4 3.9 ± 0.9 4.1 ± 1.3 6.7 ± 3.1 5.3 ± 0.9** 4.4 ± 1.8 7.6 ± 1.8* 4.8 ± 1.8 4.3 ± 0.6 9.3 ± 2.1** 4.9 ± 1.6 4.4 ± 0.9
Female 3.5 ± 1.1 2.5 ± 0.7 1.9 ± 0.5 4.8 ± 0.8 2.2 ± 0.6 2.0 ± 0.4 5.3 ± 2.0 2.5 ± 0.6 1.9 ± 0.5 5.8 ± 1.4* 2.2 ± 1.0 2.2 ± 0.4
MON 109/L Male 0.1 ± 0.0 0.0 ± 0.1 0.0 ± 0.0 0.2 ± 0.1 0.1 ± 0.0 0.0 ± 0.0 0.2 ± 0.2 0.1 ± 0.1 0.0 ± 0.0 0.3 ± 0.1 0.1 ± 0.1 0.1 ± 0.0
Female 0.1 ± 0.1 0.1 ± 0.2 0.0 ± 0.0 0.1 ± 0.1 0.0 ± 0.0 0.0 ± 0.0 0.2 ± 0.1 0.0 ± 0.0 0.0 ± 0.0 0.2 ± 0.1 0.0 ± 0.0 0.0 ± 0.0
NE 109/L Male 1.2 ± 0.3 0.6 ± 0.2 0.6 ± 0.3 1.6 ± 0.5 1.2 ± 0.3** 0.8 ± 0.3 2.6 ± 0.8** 1.2 ± 0.5** 0.9 ± 0.2 2.2 ± 0.4** 1.5 ± 0.7** 1.1 ± 0.3
Female 0.7 ± 0.3 0.5 ± 0.2 0.3 ± 0.1 1.0 ± 0.7 0.6 ± 0.2 0.4 ± 0.1 1.1 ± 0.7 0.6 ± 0.1 0.4 ± 0.1 0.9 ± 0.3 0.5 ± 0.2 0.5 ± 0.1
























Table 3 Hematological values in rats orally treated with HZJW (Continued)
Female 0.0 ± 0.1 0.0 ± 0.0 0.0 ± 0.0 0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.1 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.1 0.0 ± 0.0 0.0 ± 0.0
BAS 109/L Male 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Female 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
LYM % Male 77.7 ± 4.5 84.9 ± 0.9 86.7 ± 1.0 77.5 ± 5.2 80.7 ± 2.7** 83.4 ± 0.6** 72.8 ± 4.0 77.3 ± 2.4* 80.8 ± 1.8** 78.0 ± 4.7 75.9 ± 3.6** 79.0 ± 3.1**
Female 80.2 ± 6.1 80.0 ± 2.1 85.7 ± 0.7 80.3 ± 7.7 77.5 ± 3.7 83.9 ± 1.4* 79.8 ± 7.8 77.2 ± 2.3* 81.7 ± 2.6* 81.7 ± 6.2 78.9 ± 4.9 80.0 ± 2.0**
MON % Male 1.8 ± 0.3 1.1 ± 0.5 0.4 ± 0.1 1.9 ± 1.1 1.1 ± 0.4 0.5 ± 0.3 2.3 ± 0.7 1.4 ± 0.7 0.5 ± 0.2 2.7 ± 0.6 1.3 ± 0.5 1.1 ± 0.4
Female 1.5 ± 0.5 2.4 ± 4.3 0.3 ± 0.2 2.6 ± 0.5 0.9 ± 0.4 0.3 ± 0.3 2.7 ± 1.1 1.2 ± 0.6 0.6 ± 0.4 3.0 ± 0.6 0.9 ± 0.6 0.5 ± 0.3
NE % Male 19.5 ± 4.8 13.4 ± 0.7 12.3 ± 1.1 20.0 ± 4.8 17.6 ± 3.0** 15.8 ± 0.6 24.5 ± 4.0 20.6 ± 2.6* 18.1 ± 1.7 18.7 ± 4.3 22.0 ± 3.6** 19.3 ± 3.4
Female 16.8 ± 6.3 16.9 ± 4.4 13.8 ± 0.7 15.5 ± 7.9 20.7 ± 3.5 15.2 ± 1.5 16.6 ± 8.7 20.6 ± 2.7* 16.7 ± 2.6 14.2 ± 6.0 19.3 ± 4.1 18.7 ± 1.8
EOS % Male 0.7 ± 0.3 0.4 ± 0.3 0.4 ± 0.4 0 0.4 ± 0.3 0.3 ± 0.2 0.2 ± 0.1 0.3 ± 0.2 0.4 ± 0.3 0.4 ± 0.3 0.5 ± 0.2 0.5 ± 0.4 0.4 ± 0.2
Female 1.2 ± 0.2 0.5 ± 0.2 0.1 ± 0.1 1.0 ± 0.3 0.5 ± 0.2 0.5 ± 0.1 0.7 ± 0.5 0.7 ± 0.5 0.8 ± 0.6 0.8 ± 0.4 0.8 ± 0.5 0.5 ± 0.4
BAS % Male 0.3 ± 0.1 0.3 ± 0.2 0.2 ± 0.1 0.2 ± 0.2 0.3 ± 0.2 0.2 ± 0.1 0.1 ± 0.1 0.3 ± 0.2 0.1 ± 0.1 0.1 ± 0.1 0.3 ± 0.1 0.2 ± 0.0
Female 0.2 ± 0.2 0.3 ± 0.3 0.1 ± 0.1 0.5 ± 0.2 0.4 ± 0.3 0.1 ± 0.1 0.2 ± 0.3 0.2 ± 0.2 0.2 ± 0.3 0.3 ± 0.1 0.1 ± 0.2 0.2 ± 0.3
RET ‰ Male 11 ± 4 21 ± 5 10 ± 3 14 ± 6 18 ± 3 12 ± 2 16 ± 3* 18 ± 7 11 ± 4 14 ± 4 21 ± 5 11 ± 4
Female 18 ± 4 21 ± 4 10 ± 3 19 ± 5 22 ± 4 17 ± 2 18 ± 4 18 ± 6 11 ± 3 14 ± 4 28 ± 7 10 ± 4
Note: Red blood cell (RBC), hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular HGB (MCH), mean corpuscular HGB concentration (MCHC), red cell distribution width (RDW),
platelets (PLT), mean platelet volume (MPV), platelet distribution width (PDW), white blood cell (WBC) counts, reticulocytes (RET), neutrophils (NE), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), and
























Table 4 Serum biochemical values in rats orally treated with HZJW
Parameter unit sex
Dose (mg/kg)
0 mg/kg 1000 mg/kg 2500 mg/kg 5000 mg/kg
13 wk 26 wk Recovery 13 wk 26 wk Recovery 13 wk 26 wk Recovery 13wk 26 wk Recovery
ALT U/L Male 40 ± 3 39 ± 11 34 ± 8 31 ± 8 42 ± 11 34 ± 12 41 ± 4 34 ± 10 47 ± 14 41 ± 10 30 ± 6 37 ± 9
Female 43 ± 8 44 ± 22 32 ± 8 29 ± 8* 59 ± 32 39 ± 26 33 ± 9 39 ± 23 41 ± 43 27 ± 4** 28 ± 6 28 ± 7
AST U/L Male 161 ± 6 109 ± 28 80 ± 15 114 ± 24** 113 ± 36 91 ± 40 124 ± 13** 83 ± 13 112 ± 21 121 ± 20** 87 ± 25 105 ± 21
Female 161 ± 35 122 ± 81 78 ± 17 113 ± 18* 155 ± 72 100 ± 42 127 ± 27 104 ± 45 86 ± 71 98 ± 14** 81 ± 20 65 ± 12
LP U/L Male 90 ± 10 106 ± 38 77 ± 27 105 ± 29 70 ± 15 80 ± 43 106 ± 27 79 ± 21 84 ± 14 98 ± 22 68 ± 20 93 ± 15
Female 61 ± 19 51 ± 15 59 ± 17 60 ± 11 46 ± 18 48 ± 17 55 ± 23 54 ± 11 41 ± 22 55 ± 23 44 ± 15 57 ± 19
GLU mmol/L Male 7.26 ± 0.73 6.07 ± 0.78 7.89 ± 1.27 6.99 ± 1.49 6.69 ± 0.75 7.85 ± 1.03 6.27 ± 0.68 7.84 ± 1.30 7.48 ± 0.84 7.38 ± 0.78 8.39 ± 0.78** 8.55 ± 1.22
Female 7.60 ± 0.95 6.57 ± 0.80 7.10 ± 0.36 7.04 ± 0.83 6.81 ± 0.60 6.61 ± 0.56 6.35 ± 1.27 6.45 ± 0.63 7.02 ± 0.43 7.66 ± 1.33 7.48 ± 1.05 7.30 ± 0.35
CHOL mmol/L Male 1.20 ± 0.26 1.53 ± 0.28 1.63 ± 0.21 1.34 ± 0.33 1.44 ± 0.35 1.41 ± 0.10 1.58 ± 0.26 1.53 ± 0.36 1.73 ± 0.13 1.81 ± 0.36 1.46 ± 0.10 1.35 ± 0.21
Female 1.77 ± 0.38 2.20 ± 0.38 1.97 ± 0.47 2.14 ± 0.31 2.33 ± 0.42 2.46 ± 1.10 2.23 ± 0.39 2.25 ± 0.56 2.20 ± 0.46 2.07 ± 0.38 2.08 ± 0.44 1.92 ± 0.53
TG mmol/L Male 0.50 ± 0.06 0.66 ± 0.20 0.74 ± 0.73 0.90 ± 0.45 0.84 ± 0.36 0.85 ± 0.27 0.84 ± 0.36 0.92 ± 0.39 0.65 ± 0.16 0.74 ± 0.03** 1.01 ± 0.39* 0.74 ± 0.41
Female 0.62 ± 0.08 1.18 ± 0.62 0.70 ± 0.46 0.70 ± 0.13 0.92 ± 0.50 0.85 ± 0.28 0.58 ± 0.11 0.51 ± 0.12 0.61 ± 0.25 0.84 ± 0.32 0.75 ± 0.25 0.59 ± 0.20
TP g/L Male 5.29 ± 0.12 5.36 ± 0.29 5.54 ± 0.25 5.34 ± 0.25 5.50 ± 0.47 5.45 ± 0.18 5.70 ± 0.19** 5.37 ± 0.51 5.50 ± 0.19 5.84 ± 0.13** 5.45 ± 0.38 5.67 ± 0.22
Female 5.93 ± 0.22 6.34 ± 0.27 6.32 ± 0.42 6.31 ± 0.48 6.72 ± 0.50 6.81 ± 0.33 6.39 ± 0.27* 6.37 ± 0.43 6.32 ± 0.26 6.48 ± 0.26** 6.49 ± 0.50 6.22 ± 0.27
ALB g/L Male 3.02 ± 0.08 2.83 ± 0.34 3.04 ± 0.15 2.99 ± 0.21 2.92 ± 0.40 3.12 ± 0.13 3.33 ± 0.15** 2.86 ± 0.45 3.18 ± 0.06 3.37 ± 0.11** 2.95 ± 0.41 3.09 ± 0.13
Female 3.50 ± 0.22 3.63 ± 0.30 3.78 ± 0.35 3.69 ± 0.28 3.83 ± 0.31 4.00 ± 0.15 3.65 ± 0.19 3.64 ± 0.30 3.70 ± 0.26 3.87 ± 0.22* 3.61 ± 0.38 3.71 ± 0.17
T-BIL μmol/L Male 3.4 ± 0.4 2.9 ± 1.6 3.0 ± 2.5 3.8 ± 0.9 3.0 ± 0.7 2.4 ± 0.5 3.1 ± 0.9 3.1 ± 0.6 2.0 ± 0.4 3.5 ± 0.8 2.9 ± 1.2 2.6 ± 1.1
Female 3.9 ± 0.5 4.1 ± 1.4 3.0 ± 0.8 3.0 ± 0.7 3.6 ± 0.8 3.7 ± 0.9 3.7 ± 1.0 2.7 ± 0.6* 2.7 ± 0.5 3.1 ± 0.7 3.9 ± 0.8 2.8 ± 0.5
D-BIL μmol/L Male 2.4 ± 0.4 1.4 ± 0.5 1.8 ± 0.6 2.2 ± 0.6 1.2 ± 0.5 1.7 ± 0.2 1.2 ± 0.4 1.0 ± 0.4 1.4 ± 0.1 1.3 ± 0.6 1.1 ± 0.9 1.6 ± 0.5
Female 2.5 ± 0.1 2.0 ± 1.0 1.9 ± 0.4 1.5 ± 0.3 1.5 ± 0.6 2.5 ± 0.4 1.8 ± 0.7 0.9 ± 0.4** 1.9 ± 0.3 0.9 ± 0.2 1.4 ± 0.9 1.8 ± 0.3
Cre μmol/L Male 70.3 ± 4.6 63.6 ± 9.5 65.2 ± 10.3 74.7 ± 9.0 64.8 ± 11.9 56.1 ± 4.8 80.3 ± 10.0 62.9 ± 10.3 73.3 ± 11.8 80.5 ± 4.6 64.7 ± 4.1 76.2 ± 2.7
Female 78.8 ± 5.9 68.2 ± 8.1 67.3 ± 7.2 79.4 ± 5.2 66.9 ± 5.1 65.5 ± 3.4 82.6 ± 6.4 67.1 ± 5.7 63.2 ± 1.1 78.8 ± 8.9 71.4 ± 7.7 66.7 ± 5.3
CPK U/L Male 3214 ± 597 335 ± 141 183 ± 47 767 ± 931 325 ± 324 150 ± 46 404 ± 61 218 ± 119 301 ± 38 509 ± 220 245 ± 111 362 ± 130
Female 2032 ± 1363 244 ± 61 168 ± 89 801 ± 616 248 ± 173 231 ± 123 488 ± 143 277 ± 133 120 ± 54 264 ± 51 158 ± 44 111 ± 34
Ure mmol/L Male 4.85 ± 0.26 5.77 ± 0.82 5.17 ± 1.00 4.57 ± 0.44 5.53 ± 1.22 5.35 ± 0.66 4.23 ± 0.65 5.88 ± 0.73 5.93 ± 0.39 4.33 ± 0.43 5.66 ± 1.08 6.02 ± 1.44
Female 5.44 ± 0.49 6.08 ± 0.73 6.32 ± 0.89 5.04 ± 0.51 6.04 ± 0.92 6.13 ± 1.01 5.42 ± 0.59 6.72 ± 1.11 6.45 ± 0.67 5.71 ± 0.87 6.74 ± 1.31** 6.24 ± 1.12
Na+ mmol/L Male 141.3 ± 0.7 141.8 ± 1.4 142.3 ± 0.2 141.0 ± 0.4 142.4 ± 1.6 142.3 ± 1.2 140.7 ± 1.3 141.2 ± 0.7 141.9 ± 1.5 139.8 ± 0.7 141.1 ± 1.4 141.1 ± 0.8
























Table 4 Serum biochemical values in rats orally treated with HZJW (Continued)
K+ mmol/L Male 4.81 ± 0.27 3.95 ± 0.27 3.65 ± 0.20 5.02 ± 0.43 4.08 ± 0.64 3.50 ± 0.28 5.16 ± 0.32 4.15 ± 0.70 3.90 ± 0.20 5.13 ± 0.12 3.92 ± 0.56 4.09 ± 0.27
Female 4.43 ± 0.25 3.86 ± 0.33 3.43 ± 0.36 4.80 ± 0.34 3.57 ± 0.20 3.42 ± 0.08 4.60 ± 0.37 3.59 ± 0.27 3.46 ± 0.21 4.99 ± 0.54 4.57 ± 2.02 3.33 ± 0.31
Cl- mmol/L Male 111.1 ± 0.4 108.7 ± 2.9 107.0 ± 2.2 110.3 ± 0.9 106.7 ± 1.5 109.5 ± 1.6 108.2 ± 1.3 108.0 ± 2.9 107.2 ± 0.5 106.4 ± 1.6 107.6 ± 2.2 106.5 ± 1.2
Female 110.3 ± 3.3 108.9 ± 2.3 109.8 ± 1.6 109.7 ± 2.1 110.7 ± 1.4 109.8 ± 0.8 109.8 ± 1.6 109.2 ± 2.8 109.6 ± 1.2 107.3 ± 1.2 106.7 ± 1.6 109.1 ± 1.1
Note: Aspartate aminotransferase activity (AST), alanine aminotransferase activity (ALT), alkaline phosphatase activity (ALP), albumin (ALB), total protein (TP), glucose (GLU), total cholesterol (CHOL), creatine
phosphokinase activity (CPK), total bilirubin (T-BIL), direct bilirubin (D-BIL), creatinine (CRE), triglycerides (TG), urea (Ure), sodium ions (Na+), potassium ions (K+), chlorideions (Cl-). Values are mean ± S.D. (n = 5 (4 weeks),
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http://www.biomedcentral.com/1472-6882/13/119this ulcerogenesis model, the lesion index increased by
aspirin was observed to be counteracted by pretreatment
with HZJW of different dosages. The data obtained
demonstrated that HZJW-treated groups displayed
significant reduction in ulcerative lesion, as compared
to their control counterparts. Based on the observations
outlined, HZJW was in possession of good therapeutic
action on the gastric ulcers. The protective effect of
HZJW against the gastric damage might be due to
possible encouragement of gastric mucosal defense and/or
stimulation of endogeneous prostaglandins secretion.
However, the precise mechanism underlying this specific
action merited further exploration.
Eradication of H. pylori is an important objective in
overcoming gastric diseases. H. pylori is considered the
main etiological agent of human peptic ulcer, with a
worldwide prevalence rate of about 40% in developed
countries and over 80% in developing countries [37].
Indeed, half of all gastric ulcer cases are associated with
infection by H. pylori [38,39]. Given the major role that
H. pylori plays in the aetiology of peptic ulcers, its
eradication is strongly recommended as key for the
effective management of these pathologies [2]. In this
investigation, the in vitro anti-H. pylori properties as
well as in vivo H. pylori eradication activity of HZJW in
infected mice was assessed. Rapid urease test (RUT), with
its high sensitivity and specificity, is considered to be a
reliable test for the initial diagnosis of H. pylori infection
[40]. In the RUT assay, HZJW exhibited strong antagonistic
activity against H. pylori. HZJW were able to significantly
reduce the number of animals that presented a positive
urease test, thus preventing the colonization of H. pylori in
the stomach. The immunogold test and histopathological
analysis further confirmed the in vivo anti-H. pylori activity
of HZJW, in which HZJW could reduce the microorganism
detection in histological sections, and thereby clearing H.
pylori from the stomach of infected mice. All these results
suggested the possible in vivo efficacy in eradication
therapy for H. pylori, and this anti-H. pylori activity
should contribute to the therapeutic effect of HZJW
in treating gastrointestinal disorders.
A number of studies have shown that H. pylori
eradication by antibiotic drugs (i.e., metronidazole, amoxi-
cillin, and clarithromycin) is achieved by both systemic and
topical action [41,42]. However, HZJW displayed stronger
in vivo anti-H. pylori activity while weaker activity against
H. pylori in vitro. This suggests that the anti-H. pylori
capacity of HZJW might not result from the topical action
but may take place by a systemic action that is attributed to
the metabolic transformation of multi components in
HZJW into active intermediates. It is known that clearance
of H. pylori from the stomach of infected patients can be
due to the direct topical activity of the ingested drugs at the
gastric mucosal epithelium, and specially the secondarysystemic therapeutic activity, which result from the back
secretion and re-entry of the absorbed active principle from
the basal to the apical side of the gastric epithelium. After
absorption into the bloodstream, HZJW is postulated to be
secreted, metabolized into active forms in the liver or
during its trans-intestinal passage, from the basal side
back to the apical surface of the gastric epithelium
where H. pylori is located, thus improving the level of
clinical treatment. However, further in-depth exploration
was warranted.
The equilibrium between the therapeutic versus
toxicological effects of a drug is a vital parameter in
assessing its applicability in relation to pharmacological
action [43]. As a part of this pharmacological study, HZJW
was investigated for the acute and general toxicity in
rodents. The data obtained in acute toxicity test by a
procedure of fixed dose suggest that the oral LD50 of
HZJW in mice was over 18.0 g/kg. Anatomical results
presented the absence of abnormal organic damages in the
dead mice. During the 6-month repeated-dose (1000, 2500,
or 5000 mg/kg/day of HZJW) study, no drug-induced
variations in clinical signs or in the ophthalmological,
histopathological, hematological and blood biochemistry
were observed in any of the test-article-treated groups
compared to the recovery and control group. Throughout
the experimental period, there were no significant changes
noted in general behavior, skin effects, defecation and
postural abnormalities in all animals. Although clinical
indications like fur loss were observed in some rats, these
symptoms generally occurred spontaneously in toxicity test
due to systemic administration [44]. Additionally, these
symptoms were infrequent and not dose-dependent.
Therefore, this symptom was not considered to be a
HZJW-induced abnormality. Some changes in other clinical
observations, hematology, serum biochemistry, gross find-
ings and organ weights were considered to be not dose-
dependent and treatment-related, incidental and within the
range of normal biological variation [45]. In addition, no
corresponding histopathological findings were observed in
related organs. Therefore, these were not considered to be
triggered by HZJW.
In the histopathological examination, some rats presented
with anomalous pathologies but no significant differences
were found in relation to treatment with HZJW. No
consistent treatment-related histopathological abnormal-
ities were found in rats of either sex. These observations
are readily detected in clinically normal rats of the age and
were considered spontaneous or incidental in nature.
Therefore, these findings observed sporadically in both
sexes of the treatment groups without a dose–response
relationship were not considered to be changes triggered by
the administration of HZJW, according to the comparison
to the recovery and vehicle control group. Based on these
results, the No Observed Adverse Effect Level (NOAEL) of
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http://www.biomedcentral.com/1472-6882/13/119HZJW was considered to be 5,000 mg/kg/day for both
sexes, a dose equivalent to 50 times of normal human dose
in clinical prescription. In view of the doses of the compo-
nents consumed, HZJW was extrapolated to offer a wide
margin of safety by oral route. However, since toxicity
in animals and humans is genetically diverse and may
respond differently, especially with respect to conditions of
gastrointestinal disorders, additional toxicological assess-
ment in other species, such as dogs, needs to be performed
to evaluate the safety of HZJM, and careful observation
should be also conducted in clinical practice.Conclusions
Taken together the present results, the efficacy and safety
of HZJW in healing peptic ulcer and combating H. pylori
were demonstrated. The findings outlined corroborated
their conventional indications, and contributed to
their antiulcer pharmacological validation, lending
more credence to clinical applications for the traditional
treatment of stomach complaints symptomatic of peptic
ulcer disease (PUD). Therefore, HZJW might have the
potential for further development as a safe and effective
alternative/complementary to conventional medication in
treating gastrointestinal (GI) disorders.Additional file
Additional file 1: Figure S1. HPLC Chromatogram of HZJW and its
components. HZJW and its main compounds were subjected to HPLC.
The chromatograms were obtained at 335 nm. (A): HZJW without
Coptidis Rhizoma Scutellarin; (B) HZJW without Scutellariae Barabtae Herba;
(C) HZJW without Cynanchi Paniculati Radix et Rhizoma; (D) Standard
mixture of three major compounds: (1) scutellarin (10.35min), (2)
berberine (21.67 min), (3) paeonol (25.94 min);(E) HZJW.Abbreviations
TCM: Traditional Chinese Medicine; RUT: Rapid urease test; NSAID: Nonsteroidal
anti-inflammatory drug; PUD: Peptic ulcer disease; MIC: Minimum inhibitory
concentration; NOAEL: No Observed Adverse Effect Level; RBC: Red blood cell;
HGB: Hemoglobin; HCT: Hematocrit; MCV: Mean corpuscular volume;
MCH: Mean corpuscular hemoglobin; MCHC: Mean corpuscular hemoglobin
concentration; RDW: Red cell distribution width; PLT: Platelets; MPV: Mean
platelet volume; PDW: Platelet distribution width; WBC: White blood cell counts;
RET: Reticulocytes; NE: Neutrophils; LYM: Lymphocytes; MON: Monocytes;
EOS: Eosinophils; BAS: Basophils; PT: Prothrombin time; AST: Aspartate
aminotransferase activity; ALT: Alanine aminotransferase activity; ALP: Alkaline
phosphatase activity; ALB: Albumin; TP: Total protein; GLU: Glucose; CHOL: Total
cholesterol; CPK: Creatine phosphokinase activity; T-BIL: Total bilirubin; D-
BIL: Direct bilirubin; CRE: Creatinine; TG: Triglycerides; Ure: Urea; Na+: Sodium
ions; K+: Potassium ions; Cl-: Chlorideions.
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